BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 25499883)

  • 1. Novel heterocyclic scaffolds of GW4064 as farnesoid X receptor agonists.
    Smalley TL; Boggs S; Caravella JA; Chen L; Creech KL; Deaton DN; Kaldor I; Parks DJ
    Bioorg Med Chem Lett; 2015 Jan; 25(2):280-4. PubMed ID: 25499883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064.
    Bass JY; Caldwell RD; Caravella JA; Chen L; Creech KL; Deaton DN; Madauss KP; Marr HB; McFadyen RB; Miller AB; Parks DJ; Todd D; Williams SP; Wisely GB
    Bioorg Med Chem Lett; 2009 Jun; 19(11):2969-73. PubMed ID: 19410460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties.
    Flesch D; Gabler M; Lill A; Gomez RC; Steri R; Schneider G; Stark H; Schubert-Zsilavecz M; Merk D
    Bioorg Med Chem; 2015 Jul; 23(13):3490-8. PubMed ID: 25934227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A formulation-enabled preclinical efficacy assessment of a farnesoid X receptor agonist, GW4064, in hamsters and cynomolgus monkeys.
    Chiang PC; Thompson DC; Ghosh S; Heitmeier MR
    J Pharm Sci; 2011 Nov; 100(11):4722-33. PubMed ID: 21660973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel substituted isoxazole FXR agonists with cyclopropyl, hydroxycyclobutyl and hydroxyazetidinyl linkers: Understanding and improving key determinants of pharmacological properties.
    Kinzel O; Steeneck C; Schlüter T; Schulz A; Gege C; Hahn U; Hambruch E; Hornberger M; Spalwisz A; Frick K; Perović-Ottstadt S; Deuschle U; Burnet M; Kremoser C
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3746-53. PubMed ID: 27268696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of Novel Farnesoid X Receptor Agonists and Validation of Their Efficacy in Activating Differentiation of Mouse Bone Marrow-Derived Mesenchymal Stem Cells into Osteoblasts.
    Fujimori K; Iguchi Y; Yamashita Y; Gohda K; Teno N
    Molecules; 2019 Nov; 24(22):. PubMed ID: 31744088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knocking on FXR's door: the "hammerhead"-structure series of FXR agonists - amphiphilic isoxazoles with potent in vitro and in vivo activities.
    Gege C; Kinzel O; Steeneck C; Schulz A; Kremoser C
    Curr Top Med Chem; 2014; 14(19):2143-58. PubMed ID: 25388536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.
    Yu DD; Lin W; Chen T; Forman BM
    Bioorg Med Chem; 2013 Jul; 21(14):4266-78. PubMed ID: 23688559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unbinding pathways of GW4064 from human farnesoid X receptor as revealed by molecular dynamics simulations.
    Li W; Fu J; Cheng F; Zheng M; Zhang J; Liu G; Tang Y
    J Chem Inf Model; 2012 Nov; 52(11):3043-52. PubMed ID: 23101941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Farnesoid X receptor agonist GW4064 indirectly inhibits HCV entry into cells via down-regulating scavenger receptor class B type I.
    Wu ZY; Li H; Li JR; Lv XQ; Jiang JD; Peng ZG
    Eur J Pharmacol; 2019 Jun; 853():111-120. PubMed ID: 30902657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformationally constrained farnesoid X receptor (FXR) agonists: alternative replacements of the stilbene.
    Akwabi-Ameyaw A; Caravella JA; Chen L; Creech KL; Deaton DN; Madauss KP; Marr HB; Miller AB; Navas F; Parks DJ; Spearing PK; Todd D; Williams SP; Wisely GB
    Bioorg Med Chem Lett; 2011 Oct; 21(20):6154-60. PubMed ID: 21890356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-guided modification of isoxazole-type FXR agonists: Identification of a potent and orally bioavailable FXR modulator.
    Luo G; Lin X; Li Z; Xiao M; Li X; Zhang D; Xiang H
    Eur J Med Chem; 2021 Jan; 209():112910. PubMed ID: 33049605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Farnesoid X receptor agonists attenuate colonic epithelial secretory function and prevent experimental diarrhoea in vivo.
    Mroz MS; Keating N; Ward JB; Sarker R; Amu S; Aviello G; Donowitz M; Fallon PG; Keely SJ
    Gut; 2014 May; 63(5):808-17. PubMed ID: 23916961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Farnesoid X Receptor Agonist GW4064 Inhibits Aromatase and ERβ Expression in Human Endometriotic Stromal Cells.
    Wu PL; Zeng C; Zhou YF; Yin L; Yu XL; Xue Q
    Reprod Sci; 2019 Aug; 26(8):1111-1120. PubMed ID: 30428773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of farnesoid X receptor agonist on adiponectin and its receptors].
    Xin X; Zhong M; Zhang S; Peng Y; Zhu W; Zhang Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2014 Jan; 34(1):109-12. PubMed ID: 24463129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FXR agonist activity of conformationally constrained analogs of GW 4064.
    Akwabi-Ameyaw A; Bass JY; Caldwell RD; Caravella JA; Chen L; Creech KL; Deaton DN; Madauss KP; Marr HB; McFadyen RB; Miller AB; Navas F; Parks DJ; Spearing PK; Todd D; Williams SP; Bruce Wisely G
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4733-9. PubMed ID: 19586769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knockdown of ATP8B1 expression leads to specific downregulation of the bile acid sensor FXR in HepG2 cells: effect of the FXR agonist GW4064.
    Martínez-Fernández P; Hierro L; Jara P; Alvarez L
    Am J Physiol Gastrointest Liver Physiol; 2009 May; 296(5):G1119-29. PubMed ID: 19228886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064.
    Akwabi-Ameyaw A; Bass JY; Caldwell RD; Caravella JA; Chen L; Creech KL; Deaton DN; Jones SA; Kaldor I; Liu Y; Madauss KP; Marr HB; McFadyen RB; Miller AB; Navas F; Parks DJ; Spearing PK; Todd D; Williams SP; Wisely GB
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4339-43. PubMed ID: 18621523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist.
    Feng S; Yang M; Zhang Z; Wang Z; Hong D; Richter H; Benson GM; Bleicher K; Grether U; Martin RE; Plancher JM; Kuhn B; Rudolph MG; Chen L
    Bioorg Med Chem Lett; 2009 May; 19(9):2595-8. PubMed ID: 19328688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene.
    Bass JY; Caravella JA; Chen L; Creech KL; Deaton DN; Madauss KP; Marr HB; McFadyen RB; Miller AB; Mills WY; Navas F; Parks DJ; Smalley TL; Spearing PK; Todd D; Williams SP; Wisely GB
    Bioorg Med Chem Lett; 2011 Feb; 21(4):1206-13. PubMed ID: 21256005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.